🇺🇸 Iparomlimab in United States

15 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 15

Most-reported reactions

1. Myelosuppression — 4 reports (26.67%)
2. Pyrexia — 2 reports (13.33%)
3. White Blood Cell Count Decreased — 2 reports (13.33%)
4. Abdominal Mass — 1 report (6.67%)
5. Abdominal Pain — 1 report (6.67%)
6. Cardiac Failure Acute — 1 report (6.67%)
7. Diarrhoea — 1 report (6.67%)
8. Drug-Induced Liver Injury — 1 report (6.67%)
9. Febrile Neutropenia — 1 report (6.67%)
10. Granulocytopenia — 1 report (6.67%)

Source database →

Frequently asked questions

Is Iparomlimab approved in United States?

Iparomlimab does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Iparomlimab in United States?

Tianjin Medical University Cancer Institute and Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.